ClinicalTrials.gg
Not yet recruitingNCT07879911Updated Oct 19, 2026

A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast Cancer

A Phase 3 interventional study of Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043 and Investigator's Choice of Chemotherapy (paclitaxel,nab paclitaxel,capecitabine,eribulin,carboplatin) in Triple Negative Breast Cancer, sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

How we know

Updated Oct 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a randomized, controlled, open-label, multicenter study. Eligible participants are patients with unresectable locally recurrent or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy. Participants may be PD-L1 negative; or PD-L1 positive with disease recurrence after PD-1/PD-L1 inhibitor therapy in the neoadjuvant/adjuvant setting; or PD-L1 positive who cannot tolerate PD-1/PD-L1 inhibitor therapy due to other underlying comorbidities.

Approximately 550 participants will be enrolled and randomized at a 1:1 ratio to the experimental group or the control group. All enrolled participants will continue study treatment until BICR-confirmed disease progression, no further clinical benefit as judged by the investigator, unacceptable toxicity, withdrawal of informed consent, loss to follow-up, death, or end of study, whichever occurs first.

Upon discontinuation of study treatment, participants will complete the end-of-treatment (EOT) visit and safety follow-up. Survival visits will be performed every 3 months (±14 days) after the last study drug administration to collect participants' survival status and information regarding subsequent anti-tumor therapies

02

Conditions studied

  • Triple Negative Breast Cancer
03

In context

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 443 are open to participants now.

This study's planned enrollment of 550 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd. is the lead sponsor of 42 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 and ≤ 75 years at the time of signing the form, with no restriction on sex.
  2. and/or cytologically confirmed triple negative breast cancer (TNBC) meeting both of the following criteria: a) Human epidermal growth factor receptor 2 () negative; b) Estrogen receptor (ER) negative and progesterone receptor (PR) negative.
  3. De novo disease, or unresectable recurrent and/or metastatic disease occurring after completion of curative intent therapy.
  4. No prior systemic anti tumor therapy for unresectable recurrent or metastatic disease.
  5. PD L1 expression determined by the sponsor designated central laboratory using tumor tissue collected at screening. Participants must meet either: a) PD L1 negative expression (CPS \< 10); OR b) PD L1 positive expression (CPS ≥ 10).
  6. At least one per version 1.1.
  7. (ECOG) performance status of 0 or 1.
  8. Expected survival of at least 12 weeks.
  9. Deemed by the investigator to be suitable for one of the investigator's choice chemotherapy regimens (paclitaxel, nab paclitaxel, capecitabine, eribulin, or carboplatin).
  10. Adequate organ and bone marrow function (no transfusion, recombinant human thrombopoietin, or colony stimulating factor within 2 weeks prior to randomization).
  11. Participants must have recovered from all toxicities attributable to prior therapies (recovered to Grade ≤ 1 per Version 6.0, or otherwise meeting protocol specified entry criteria).
  12. Serum pregnancy test negative within 7 days prior to randomization for women of child bearing potential.
  13. Voluntarily agrees to participate in this study, provides signed informed consent, and is able to comply with protocol required visits and procedures.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of another within 3 years prior to randomization.
  2. Presence of spinal cord compression, clinically active brain metastase.
  3. Presence of cardiovascular and cerebrovascular diseases or cardiovascular cerebrovascular risk factors.

4 History of non infectious interstitial lung disease (ILD) or non infectious pneumonitis requiring therapy.

5 pulmonary impairment secondary to underlying pulmonary disease.

6 Tumor invasion into adjacent vital organs and blood vessels. 7 Severe infection occurring within 4 weeks prior to randomization. 8 History of esophageal and gastric varices, severe ulcer, gastrointestinal perforation, gastrointestinal obstruction, intra abdominal abscess, or acute gastrointestinal bleeding within 6 months prior to randomization.

9 Active or well documented prior history of inflammatory bowel disease. 10 Uncontrolled systemic disease as judged by the investigator. 11 Participants with active viral hepatitis; positive virus (HCV) with HCV RNA above the lower limit of quantification of the assay.

12 Positive (HIV) test or history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.

13 Known to active pharmaceutical ingredients or of study drug.

14 Known history of allogeneic solid organ transplantation or hematopoietic stem cell transplantation.

15 Pregnant or breastfeeding women. 16 Prior receipt of B7 H3 targeted therapy; prior irinotecan, topotecan, or any chemotherapy agents targeting topoisomerase I (including ADCs).

17 Prior treatment with the same agent as the investigator selected chemotherapy.

18 administered within 4 weeks before randomization, or planned administration of live vaccine during study treatment.

19 Insufficient for prior anti tumor therapy before the first dose of study drug.

20 Chronic concomitant use of systemic corticosteroids or other agents.

21 Local or systemic disease unrelated to malignancy, or diseases/symptoms secondary to tumor.

22 Any condition that, in the investigator's opinion, would interfere with the evaluation of study drug, participant safety, or interpretation of study results, or any other condition rendering the participant unsuitable for study participation as assessed by the investigator.

23 Systemic administration of strong / CYP2C8 inhibitors or strong inducers, or OATP1B1 / OATP1B3 inhibitors within 14 days prior to the first dose of study drug, or requiring continued systemic use of such agents during study treatment.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    SYS6043

    Biological: Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043

  • Active comparator
    Investigator's Choice of Chemotherapy (paclitaxel,nab paclitaxel,capecitabine,eribulin,carboplatin)

    Drug: Investigator's Choice of Chemotherapy (paclitaxel,nab paclitaxel,capecitabine,eribulin,carboplatin)

Interventions

  • BiologicalGeneric DrugStudies of Generic DrugGeneric Drug pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Add details that will distinguish this intervention from other interventions in this or another clinical study. Participants in the experimental group will receive SYS6043, administered on Day 1 of each cycle,Q3W.

  • DrugInvestigator's Choice of Chemotherapy (paclitaxel,nab paclitaxel,capecitabine,eribulin,carboplatin)

    Add details that will distinguish this intervention from other interventions in this or another clinical study. Paclitaxel (90 mg/m², intravenous, Days 1, 8, and 15 of each 4 week cycle \[Q4W\]; or 80 mg/m², intravenous, Days 1, 8, and 15 of each 3 week cycle \[Q3W\]); Nab paclitaxel (100 mg/m², intravenous, Days 1, 8, and 15, Q4W); Capecitabine (1000 1250 mg/m², orally, twice daily on Days 1 14, Q3W); Eribulin (1.4 mg/m², intravenous, Days 1 and 8, Q3W); Carboplatin (administered on Day 1 at an area under the curve \[AUC\] of 6, Q3W).

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Assessed by BICR per RECIST 1.1

    Progression free survival is defined as the time from randomization to the first documented disease progression per RECIST version 1.1 or death from any cause, whichever occurs first. Disease progression is centrally reviewed by a blinded independent imaging review committee to eliminate assessment bias.

    Time frame: Up to approximately 5 years

  2. Overall Survival (OS)

    Overall survival is defined as the time from randomization to death from any cause. For participants who are not deceased, survival time will be censored at the last known date the participant was known to be alive.

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Objective Response Rate (ORR) assessed by BICR/Investigator per RECIST 1.1

    Objective Response Rate (ORR) is the proportion of participants achieving confirmed complete response (CR) or partial response (PR) per RECIST version 1.1. ORR will be evaluated by both Blinded Independent Central Review (BICR) and investigator (INV).

    Time frame: Up to approximately 5 years

  2. Disease Control Rate (DCR) assessed by BICR/Investigator per RECIST 1.1

    Disease Control Rate (DCR) is defined as the percentage of participants with confirmed complete response (CR), partial response (PR), or stable disease (SD) per RECIST version 1.1. DCR will be evaluated by both Blinded Independent Central Review (BICR) and investigator (INV).

    Time frame: Up to approximately 5 years

  3. Duration of Response (DoR) assessed by BICR/Investigator per RECIST 1.1

    Duration of Response (DoR) is defined as the time from the date of first documented confirmed objective response (CR or PR) per RECIST version 1.1 to the date of documented disease progression or death from any cause, whichever occurs first. DoR will be evaluated by both Blinded Independent Central Review (BICR) and investigator (INV)

    Time frame: Up to approximately 5 years

  4. Time To Response (TTR) assessed by BICR/Investigator per RECIST 1.1

    Time To Response (TTR) is defined as the time from randomization to the date of first documented confirmed objective response (CR or PR) per RECIST version 1.1 among participants who achieve an objective response. TTR will be evaluated by both Blinded Independent Central Review (BICR) and investigator (INV).

    Time frame: Up to approximately 5 years

  5. Time to First Subsequent Therapy(TFST)

    Time to First Subsequent Therapy (TFST) is defined as the time from randomization to the start date of the first subsequent anti-cancer therapy after discontinuation of randomized study treatment, or death from any cause, whichever occurs first.

    Time frame: Up to approximately 5 years

  6. Time to Second Subsequent Therapy (TSST)

    Time to Second Subsequent Therapy (TSST) is defined as the time from randomization to the start date of the second subsequent anti-cancer therapy after discontinuation of randomized study treatment, or death from any cause, whichever occurs first.

    Time frame: Up to approximately 5 years

  7. Incidence and Titer of Anti Drug Antibody (ADA) against SYS6043, and Incidence of Neutralizing Antibody (NAb), if applicable

    The incidence and titer of anti drug antibody (ADA) against SYS6043 will be evaluated from serum samples. The incidence of neutralizing antibody (NAb) will be assessed among ADA positive participants, if applicable.

    Time frame: Up to approximately 5 years

  8. Patient-Reported Quality of Life Scores Evaluated by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

    Participants' quality of life will be assessed using the symptom domain scales of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) is a 30-item patient-reported questionnaire. All transformed subscale scores range from 0 to 100. For the functional scales and global health status scale, higher scores represent better functioning and quality of life. For symptom scales, higher scores indicate more severe symptoms (worse outcome).

    Time frame: Up to approximately 5 years

  9. Patient Reported Quality of Life Scores Evaluated by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module 42(EORTC QLQ BR42).

    Participants' quality of life will be assessed using the symptom domain scales of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module 42 (EORTC QLQ-BR42). This is a 42-item breast cancer-specific patient-reported questionnaire. All transformed subscale scores range from 0 to 100. For functional scales, higher scores represent better functioning. For symptom scales, higher scores indicate more severe symptoms (worse outcome)

    Time frame: Up to approximately 5 years

Other outcomes

  1. Correlation Between Efficacy and Expression Levels of Biomarkers Including B7 H3

    Exploratory analysis will be performed to evaluate the correlation between tumor biomarker expression levels including B7 H3 and anti tumor efficacy endpoints

    Time frame: Up to approximately 5 years

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.

Of 60 phase 3 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 19, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Nov 30, 2028
CompletionEst.
May 30, 2029
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07879911
Responsible party
Sponsor
First posted
Oct 19, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Nov 30, 2028 (estimated)
Completion
May 30, 2029 (estimated)
Last update
Oct 19, 2026

Study contacts

Jian Zhang
Contact
syner2000@163.com
021-64175590

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Generic Drug

Start the discussion